Immune Thrombocytopenia Management

Introduction

• Immune thrombocytopenia (ITP) is a condition characterized by low platelet count, and its management involves a comprehensive approach, including diagnosis, treatment, and monitoring, as recommended by the American Society of Hematology 1, 2

Diagnosis and Evaluation

• The diagnostic workup for ITP includes complete blood count with peripheral smear, basic metabolic panel, liver function tests, and coagulation studies (PT, PTT), as recommended by the American Society of Hematology 1
• Testing for HIV, hepatitis C, H. pylori infection, and antinuclear antibodies may be considered in certain cases, and bone marrow examination may be considered if abnormal cells are present on peripheral smear or if atypical features are noted 1
• A family history of thrombocytopenia should be considered in the initial evaluation, and evidence of thrombosis should be assessed in patients with thrombocytopenia 3
• Distinguishing between true thrombocytopenia and pseudothrombocytopenia is crucial, with pseudothrombocytopenia occurring in ~0.1% of adults, as recommended by the American Society of Hematology 3

First-Line Treatment

• For patients with ITP presenting with bleeding and low platelet count, immediate treatment with intravenous immunoglobulin (IVIg) at a dose of 0.8-1 g/kg as a single dose is recommended, along with high-dose corticosteroids, as per the American Society of Hematology guidelines 2
• IVIg raises platelet count in more than 80% of patients and works more rapidly than corticosteroids alone, typically producing response within 1-2 days 2
• High-dose corticosteroids, such as prednisone 1-2 mg/kg/day or high-dose methylprednisolone 30 mg/kg/day for 3 days, have a response rate of 72-88% within 72 hours 2
• First-line treatment includes a combination of local measures and systemic therapy with either IVIg or corticosteroids to rapidly increase platelet count and control bleeding, with a response rate of 72-88% within 72 hours with corticosteroids, and >80% within 1-2 days with IVIg 2, 1

Special Considerations

• For pregnant women with ITP, treatment with corticosteroids or IVIg is recommended, and delivery method should be based on obstetric indications, as recommended by the American Society of Hematology 1
• For patients with lupus-associated thrombocytopenia, treatment with glucocorticoids and immunosuppressive agents (AZA, MMF, or cyclosporine) is recommended, as recommended by the American College of Rheumatology 4
• For patients who are Rh(D) positive, IV anti-D immunoglobulin can be considered as an alternative to IVIg 2
• Antiviral therapy may be considered for HCV-associated ITP, and antiretroviral therapy is recommended for HIV-associated ITP before other treatment options, with eradication therapy recommended for confirmed H. pylori infection-associated ITP 1

Second-Line Treatment and Beyond

• The American Society of Hematology recommends transitioning to second-line therapy in cases of failure to respond to first-line therapy, relapse after initial response, or need for prolonged corticosteroid use 5
• Thrombopoietin receptor agonists (TPO-RAs) are recommended for patients who have failed corticosteroid therapy or who relapse after splenectomy, and rituximab may be considered for patients with significant ongoing bleeding despite first-line treatment, or as an alternative to splenectomy 1
• Splenectomy may be considered for patients who have failed corticosteroid therapy, but is associated with serious short- and long-term risks 5

Management of Bleeding and Thrombosis

• If bleeding is severe or life-threatening, combination therapy of platelet transfusions + high-dose corticosteroids + IVIg can be used, with a recommended platelet transfusion dose of 2-3 fold larger-than-usual 2, 3
• Platelet transfusions are indicated only in cases of life-threatening bleeding or prior to urgent procedures, according to the American Society of Anesthesiologists 2
• For cancer patients with thrombocytopenia and thrombosis, anticoagulation should be adjusted based on platelet count thresholds, with full therapeutic anticoagulation for platelet count ≥50 × 10^9/L, reduced LMWH to 50% of therapeutic dose or prophylactic dose for platelet count 25-50 × 10^9/L, and temporary discontinuation of anticoagulation for platelet count <25 × 10^9/L 6, 7

Monitoring and Follow-Up

• Monitor platelet counts within 24 hours of initiating treatment, then daily until stable, and educate patients about avoiding activities with high risk of trauma 1
• Patients with ITP require regular follow-up with complete blood counts, as suggested by the American Society of Clinical Oncology 2
• Consider long-term management options for chronic ITP if epistaxis is recurrent 1

Risk Stratification

• The International Prognostic Scoring System (IPSS-R) score is used for risk stratification in MDS, guiding treatment decisions, as recommended by the Annals of Oncology 8